Dr. Shallis received his MD from Rutgers-Robert Wood Johnson Medical School, completed his residency training at Brown University-Rhode Island Hospital and fellowship training at Yale-New Haven Hospital.
He is focused on the care and research of patients with myeloid malignancies, particularly acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). He also participated in the K12 Calabresi Immuno-Oncology Training Program and currently participates as an investigator in several clinical trials aimed at improving the outcomes of patients with AML and MDS.
Dr. Shallis also maintains research interest in epidemiological, outcomes and effectiveness research as it pertains to the hematologic malignancies with a goal of identifying barriers to effective care and ultimately strategies to improve the outcomes of patients with these malignant diseases. Dr. Shallis conducts research with the Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center at Yale University.
Dr. Shallis has presented his research at multiple regional, national and international meetings and is a member of the National Comprehensive Cancer Network (NCCN) clinical guidelines for MDS and AML panels. He is an author on more than 75 peer-reviewed publications and book chapters, most of which as first author and has served as an ad hoc reviewer for many journals including Leukemia, Haematologica, Blood Advances, Leukemia Research, Leukemia & Lymphoma, Acta Haematologica, Hematology, Therapeutic Advances in Hematology, Expert Review of Hematology, BMC Hematology, eJHaem and Future Oncology among others.
|Top Overall Abstract||Myeloid Malignancies Symposium||2020|
|Hematology/Oncology Fellowship Program Research Award||Yale Cancer Center||2019|
|National Comprehensive Cancer Network (NCCN) - Myelodysplastic Syndromes Guideline Panel||Member||2020 - Present|
|Older Adult AML Working Group - National Cancer Institute (NCI) Myeloid Precision Medicine Initiative||Member||2020 - Present|
|ECOG-ACRIN Leukemia Committee||Member||2020 - Present|
|American Society of Hematology (ASH)||Member||2017 - Present|
|American Society of Clinical Oncology (ASCO)||Member||2017 - Present|